Summary

• Investors in cannabinoid biotech and pharmaceutical stocks are investing in a whole different side of the cannabis movement.

• Rather that working to put joints in the hands of smokers, these companies are working to get drugs passed by the FDA to treat serious conditions like epilepsy and MS.

• While biotech is off to a great start this year, a handful of cannabinoid-pharma companies seem to be the real winners. ​

• With Jeff Session as U.S. attorney general, we believe cannabinoid pharma could be one of the safer ways to invest in the green rush.

Go check out our entire article about cannabinoid pharma & biotech on Seeking Alpha!